



METHOD FOR EARLY TAKO-TSUBO CARDIOMIOPHATY PROGNOSIS IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE

The Need

Aneurysmal subarachnoid haemorrhage represents a serious medical emergency with high mortality and morbidity due to early rebleeding. Approximately 11% of these patients die before receiving medical attention and 40% die within 4 weeks after admission to hospital. Among survivors 30% have a considerable limitation for activities of daily living and often suffer from cardiac

complications associated with an increased risk of short-term death. Tako-Tsubo cardiomyopathy (TTC) is the main cardio-dysfunction that occurs after neurological damage The prevalence in SAH 's patients is between 20% and 30%, with a higher prevalence in women. There is a medical need in predicting risk of TTC in early SAH stages in order to adapt accordingly their treatment and monitoring.

The Solution

The technology provides an in vitro method able to predict, at day 0 with 100% efficiency, patients with a subarachnoid aneurysmal haemorrhage that will develop a complication of Tako-Tsubo cardiomyopathy and therefore should follow a preventive treatment and monitoring.

The solution is based in determining the combined level of two molecules or their mRNA in serum/ blood samples obtained from the patient at emergency arrival.

Innovative Aspects

- Early prediction of SAH complications into a TTC cardiomyopathy.
- Rapid and easy identification of patients.
- Preventive treatment and monitoring of these patients.
- Reduction of severity effects and mortality.
- Minimally invasive method from serum or blood samples
- The IVD can be easily implemented to be performed in health services' currently available devices

Stage of Development:

The method is currently being validated by the group in a bigger cohort of patients arriving though emergency services at hospitals.

Intellectual Property:

• Spanish patent filed (3rd March 2021)

Aims

Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.



Contact details

Centro de Investigación Biomédica en Red (CIBER) otc@ciberisciii.es transferencia@ciberisciii.es https://www.ciberisciii.es/en